Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CARLSMED, INC.CARL · Entity 5551 | 10% owner | July 24, 2025 | September 15, 2026 |
| Heartflow, Inc.HTFL · Entity 3993 | Director | June 16, 2026 | June 18, 2026 |
| Inspire Medical Systems, Inc.INSP · Entity 1186 | Director | July 15, 2026 | July 18, 2026 |
| Intersect ENT, Inc.XENT · Entity 127294 | Director | June 01, 2017 | June 05, 2017 |
| Mobia Medical, Inc.MOBI · Entity 5669 | Director | August 18, 2026 | August 21, 2026 |
| SHOULDER INNOVATIONS, INC.SI · Entity 5607 | Director · 10% owner | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CARLSMED, INC.
Report date July 24, 2025 · Filed September 15, 2026 · Amendment
Jointly reported with Presidio Management Group XII, L.L.C., U.S. Venture Partners XII, L.P.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 200,000 |
Reported balance
After 2025-07-24 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-07-24 · Purchase · Acquired 200,000 · Balance 200,000 F1: Stock held by Casey M. Tansey. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock held by Casey M. Tansey.
Heartflow, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $32.05 · Expires 2036-06-16 | Direct | 16,075 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 16,075 · Balance 16,075 F1: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.
Inspire Medical Systems, Inc.
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,632 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 346 · Balance 26,632 F1: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 500 |
Reported balance
Holding disclosure · report date 2026-07-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 500 F2: Securities held by The Kimberly Tansey Irrevocable Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 500 |
Reported balance
Holding disclosure · report date 2026-07-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 500 F3: Securities held by The Kylie Tansey Irrevocable Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.
F2: Securities held by The Kimberly Tansey Irrevocable Trust.
F3: Securities held by The Kylie Tansey Irrevocable Trust.
Intersect ENT, Inc.
Report date June 01, 2017 · Filed June 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,546 |
Reported balance
After 2017-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-06-01 · Grant · Acquired 2,546 · Balance 2,546 F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.05 · Expires 2027-05-31 | Direct | 6,035 |
Reported balance
After 2017-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-01 · Grant · Acquired 6,035 · Balance 6,035 F2: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018.
F2: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017.
Mobia Medical, Inc.
Report date August 18, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 318,332 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Purchase · Acquired 16,441 · Balance 318,332 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.90 to $12.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.90 to $12.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
SHOULDER INNOVATIONS, INC.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,445 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 733 · Balance 53,445 F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. |
| Common StockSEC Table I · non-derivative | IndirectHeld by U.S. Venture Partners XII, L.P. | 1,686,403 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,686,403 F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. |
| Common StockSEC Table I · non-derivative | IndirectHeld by U.S. Venture Partners XII-A, L.P. | 85,586 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 85,586 F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. |
| Common StockSEC Table I · non-derivative | IndirectHeld by U.S. Venture Partners Select Fund I, L.P. | 921,130 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 921,130 F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.
F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A.
F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARS Pharmaceuticals, Inc.
Report date December 08, 2020 · Filed December 09, 2020
Jointly reported with Presidio Management Group XII, L.L.C., U.S. Venture Partners XII, L.P., U.S. Venture Partners XII-A, L.P.
Section 16 reporting ended · disclosed 2020-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy U.S. Venture Partners XII, L.P. | 2,069,167 |
Last balance in matching sequence
After 2020-12-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-12-08 · Conversion · Acquired 1,779,969 · Balance 1,779,969 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 2 · 2020-12-08 · Conversion · Acquired 289,198 · Balance 2,069,167 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy U.S. Venture Partners XII-A, L.P. | 105,012 |
Last balance in matching sequence
After 2020-12-08 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 3 · 2020-12-08 · Conversion · Acquired 90,335 · Balance 90,335 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 4 · 2020-12-08 · Conversion · Acquired 14,677 · Balance 105,012 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Tansey | 47,619 |
Reported balance
After 2020-12-08 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2020-12-08 · Purchase · Acquired 47,619 · Balance 47,619 F1: The shares were purchased in the Issuer's initial public offering. |
| Preferred Series B StockSEC Table II · derivative / convertible security | IndirectBy U.S. Venture Partners XII, L.P. | 0 |
Reported balance
After 2020-12-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-08 · Conversion · Disposed 6,609,027 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Preferred Series B StockSEC Table II · derivative / convertible security | IndirectBy U.S. Venture Partners XII-A, L.P. | 0 |
Reported balance
After 2020-12-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-08 · Conversion · Disposed 335,417 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Preferred Series C StockSEC Table II · derivative / convertible security | IndirectBy U.S. Venture Partners XII, L.P. | 0 |
Reported balance
After 2020-12-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-12-08 · Conversion · Disposed 1,073,793 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Preferred Series C StockSEC Table II · derivative / convertible security | IndirectBy U.S. Venture Partners XII-A, L.P. | 0 |
Reported balance
After 2020-12-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-12-08 · Conversion · Disposed 54,496 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were purchased in the Issuer's initial public offering.
F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.
F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
BOX INC
Report date June 02, 2017 · Filed June 08, 2017 · Amendment
Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, FEDERMAN IRWIN, LIDDLE DAVID E, Matteucci Paul A, ROOT JONATHAN D, YOUNG PHILIP M
Section 16 reporting ended · disclosed 2017-06-08. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP IX | 0 |
Last balance in matching sequence
After 2017-06-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-06-02 · Conversion · Acquired 8,000,000 · Balance 8,000,000 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 2 · 2017-06-02 · Other · Disposed 8,000,000 · Balance 0 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2: Prorata distribution in kind from the partnership without consideration to its limited partners. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectDirectly owned by USVP IX | 3,713,775 |
Reported balance
After 2017-06-02 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2017-06-02 · Conversion · Disposed 8,000,000 · Balance 3,713,775 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F2: Prorata distribution in kind from the partnership without consideration to its limited partners.
F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
INTERMOLECULAR INC
Report date November 08, 2018 · Filed November 13, 2018
Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, KRAUSZ STEVEN M, LIDDLE DAVID E, Matteucci Paul A, ROOT JONATHAN D, YOUNG PHILIP M
Section 16 reporting ended · disclosed 2018-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by USVP IX | 0 |
Reported balance
After 2018-11-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-11-08 · Other · Disposed 4,280,779 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | Direct | 856,155 |
Reported balance
After 2018-11-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-11-08 · Other · Acquired 856,155 · Balance 856,155 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-08 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-11-08 · Other · Disposed 856,155 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Steven Krausz | 97,593 |
Last balance in matching sequence
After 2018-11-13 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 4 · 2018-11-08 · Other · Acquired 102,093 · Balance 102,093 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 5 · 2018-11-12 · Sale · Disposed 2,100 · Balance 99,993 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 6 · 2018-11-13 · Sale · Disposed 2,400 · Balance 97,593 F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by David Liddle | 69,609 |
Reported balance
After 2018-11-08 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2018-11-08 · Other · Acquired 69,609 · Balance 69,609 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Paul Matteucci | 60,408 |
Reported balance
After 2018-11-08 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2018-11-08 · Other · Acquired 60,408 · Balance 60,408 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Jonathan Root | 85,851 |
Reported balance
After 2018-11-08 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2018-11-08 · Other · Acquired 85,851 · Balance 85,851 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Casey Tansey | 60,336 |
Reported balance
After 2018-11-08 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2018-11-08 · Other · Acquired 60,336 · Balance 60,336 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Philip Young | 82,370 |
Reported balance
After 2018-11-08 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2018-11-08 · Other · Acquired 82,370 · Balance 82,370 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Inari Medical, Inc.
Report date March 16, 2021 · Filed March 18, 2021
Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP
Section 16 reporting ended · disclosed 2021-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP X | 2,619,872 |
Reported balance
After 2021-03-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-03-16 · Other · Disposed 2,619,872 · Balance 2,619,872 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by AFF X | 83,813 |
Reported balance
After 2021-03-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-03-16 · Other · Disposed 83,814 · Balance 83,813 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by PMG X. | 685,827 |
Reported balance
After 2021-03-16 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-03-16 · Other · Acquired 685,827 · Balance 685,827 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by PMG X. | 0 |
Reported balance
After 2021-03-16 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-03-16 · Other · Disposed 685,827 · Balance 0 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Tansey | 242,988 |
Reported balance
After 2021-03-16 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-03-16 · Other · Acquired 77,296 · Balance 242,988 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.
F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.
ON24 INC.
Report date August 17, 2021 · Filed August 19, 2021
Jointly reported with PRESIDIO MANAGEMENT GROUP VII L L C, US VENTURE PARTNERS VII L P, 2180 ASSOCIATES FUND VII L P, USVP ENTREPRENEUR PARTNERS VII A L P, USVP ENTREPRENEUR PARTNERS VII B L P
Section 16 reporting ended · disclosed 2021-08-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP VII | 4,368,405 |
Reported balance
After 2021-08-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-08-17 · Other · Disposed 1,500,000 · Balance 4,368,405 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by 2180-VII | 91,008 |
Reported balance
After 2021-08-17 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-08-17 · Other · Disposed 31,250 · Balance 91,008 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein |
| Common StockSEC Table I · non-derivative | Direct | 312 |
Reported balance
After 2021-08-17 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-08-17 · Other · Acquired 312 · Balance 312 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-08-18 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-08-18 · Sale · Disposed 312 · Balance 0 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by EP7-A | 45,505 |
Reported balance
After 2021-08-18 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-08-18 · Sale · Disposed 15,625 · Balance 45,505 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by EP7-B | 45,505 |
Reported balance
After 2021-08-18 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-08-18 · Sale · Disposed 15,625 · Balance 45,505 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Casey Tansey | 5,000 |
Reported balance
Holding disclosure · report date 2021-08-17 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 5,000 F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII.
F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
eFFECTOR Therapeutics, Inc.
Report date August 01, 2022 · Filed August 03, 2022
Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP, ROOT JONATHAN D
Section 16 reporting ended · disclosed 2022-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP X | 3,981,940 |
Last balance in matching sequence
After 2022-08-03 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2022-08-01 · Sale · Disposed 25,896 · Balance 4,066,868 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 3 · 2022-08-02 · Sale · Disposed 27,348 · Balance 4,039,520 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 5 · 2022-08-03 · Sale · Disposed 57,580 · Balance 3,981,940 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by AFF X | 127,569 |
Last balance in matching sequence
After 2022-08-03 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2022-08-01 · Sale · Disposed 807 · Balance 130,218 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 4 · 2022-08-02 · Sale · Disposed 853 · Balance 129,365 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 6 · 2022-08-03 · Sale · Disposed 1,796 · Balance 127,569 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 21:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | GrantCommon Stock | 733 | $19.60 | $14,366.80 |
DisclosureSEC source: 0001628280-26-065260 · wk-form4_1791320755.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,445 F1 · shares: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. Read SEC document |
| August 18, 2026 Filed Aug 21, 2026 01:05 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | PurchaseCommon Stock | 16,441 | $12.07 | $198,523.43 |
DisclosureSEC source: 0001193125-26-359683 · ownership.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,332 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.90 to $12.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 01:53 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | PurchaseCommon Stock | 17,166 | $11.85 | $203,432.55 |
DisclosureSEC source: 0001193125-26-354538 · ownership.xml · nonDerivative · entry 4 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,891 F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.675 to $12.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 01:53 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | PurchaseCommon Stock | 100 | $12.53 | $1,253.00 |
DisclosureSEC source: 0001193125-26-354538 · ownership.xml · nonDerivative · entry 3 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,725 Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 01:53 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | PurchaseCommon Stock | 15,721 | $11.65 | $183,149.65 |
DisclosureSEC source: 0001193125-26-354538 · ownership.xml · nonDerivative · entry 2 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,625 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.42 to $12.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2026 Filed Aug 18, 2026 01:53 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | PurchaseCommon Stock | 35,572 | $11.51 | $409,337.68 |
DisclosureSEC source: 0001193125-26-354538 · ownership.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,904 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.33 to $11.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:27 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 346 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-084766 · tm2620811-3_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,632 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 21:56 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | GrantCommon Stock | 5,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-046099 · wk-form4_1782770216.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,712 F1 · shares: Represents an award of restricted stock units ("RSUs"). The RSUs will vest on the earlier of the date of the annual meeting of stockholders to be held in 2027 or June 26, 2027. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:26 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantStock Option · Derivative | 16,075 | $32.05 Strike: $32.05 | $515,203.75 |
DisclosureSEC source: 0001464521-26-000085 · form4.xml · derivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,075 Underlying: Common Stock · 16,075 shares Expires 2036-06-16 F1 · derivative.exercise_date: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | ConversionSeries E-2 Preferred Stock · Derivative | 5,895,530 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · derivative · entry 11 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,692,658 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms. F5 · price: Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms. F5 · derivative.exercise_date: Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms. F5 · derivative.expiration_date: Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms. F2 · ownership.nature: After the transactions reported herein, includes (i) 1,623,245 shares of Common Stock held by U.S. Venture Partners Select Fund I, L.P. ("USVP SFI") on its own behalf and as a nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A" and, together with USVP SFI, the "USVP Select Funds"), (ii) 1,906,809 shares of Common Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"), and (iii) 96,772 shares of Common Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A" and, together with USVP XII, the "USVP XII Funds"). F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of USVP XII and USVP XII-A and may be deemed to have sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of USVP SFI and USVP SFI-A and may be deemed to have sole voting and dispositive power with respect to the securites held by USVP SFI and USVP SFI-A. F4 · ownership.nature: The Reporting Person is the managing partner and a managing member of each of PMG XII and PMG Select, and may be deemed to share voting and dispositive power with respect to the securites described herein. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | ConversionSeries F Preferred Stock · Derivative | 5,642,738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · derivative · entry 10 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,620,078 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms. F5 · price: Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms. F5 · derivative.exercise_date: Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms. F5 · derivative.expiration_date: Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms. F2 · ownership.nature: After the transactions reported herein, includes (i) 1,623,245 shares of Common Stock held by U.S. Venture Partners Select Fund I, L.P. ("USVP SFI") on its own behalf and as a nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A" and, together with USVP SFI, the "USVP Select Funds"), (ii) 1,906,809 shares of Common Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"), and (iii) 96,772 shares of Common Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A" and, together with USVP XII, the "USVP XII Funds"). F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of USVP XII and USVP XII-A and may be deemed to have sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of USVP SFI and USVP SFI-A and may be deemed to have sole voting and dispositive power with respect to the securites held by USVP SFI and USVP SFI-A. F4 · ownership.nature: The Reporting Person is the managing partner and a managing member of each of PMG XII and PMG Select, and may be deemed to share voting and dispositive power with respect to the securites described herein. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | ConversionConvertible Notes · Derivative | 2,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · derivative · entry 9 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 166,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F1 · price: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F1 · derivative.exercise_date: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F1 · derivative.expiration_date: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | ConversionConvertible Notes · Derivative | 3,769,090.08 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · derivative · entry 8 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners Select Fund I, L.P Disclosed balance after: 0 Underlying: Common Stock · 314,090 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F1 · price: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F1 · derivative.exercise_date: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F1 · derivative.expiration_date: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | ConversionCommon Stock | 3,312,736 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · nonDerivative · entry 4 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,626,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms. F2 · ownership.nature: After the transactions reported herein, includes (i) 1,623,245 shares of Common Stock held by U.S. Venture Partners Select Fund I, L.P. ("USVP SFI") on its own behalf and as a nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A" and, together with USVP SFI, the "USVP Select Funds"), (ii) 1,906,809 shares of Common Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"), and (iii) 96,772 shares of Common Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A" and, together with USVP XII, the "USVP XII Funds"). F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of USVP XII and USVP XII-A and may be deemed to have sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of USVP SFI and USVP SFI-A and may be deemed to have sole voting and dispositive power with respect to the securites held by USVP SFI and USVP SFI-A. F4 · ownership.nature: The Reporting Person is the managing partner and a managing member of each of PMG XII and PMG Select, and may be deemed to share voting and dispositive power with respect to the securites described herein. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | ConversionCommon Stock | 314,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · nonDerivative · entry 3 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 314,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F2 · ownership.nature: After the transactions reported herein, includes (i) 1,623,245 shares of Common Stock held by U.S. Venture Partners Select Fund I, L.P. ("USVP SFI") on its own behalf and as a nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A" and, together with USVP SFI, the "USVP Select Funds"), (ii) 1,906,809 shares of Common Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"), and (iii) 96,772 shares of Common Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A" and, together with USVP XII, the "USVP XII Funds"). F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of USVP XII and USVP XII-A and may be deemed to have sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of USVP SFI and USVP SFI-A and may be deemed to have sole voting and dispositive power with respect to the securites held by USVP SFI and USVP SFI-A. F4 · ownership.nature: The Reporting Person is the managing partner and a managing member of each of PMG XII and PMG Select, and may be deemed to share voting and dispositive power with respect to the securites described herein. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | PurchaseCommon Stock | 66,666 | $15.00 | $999,990.00 |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · nonDerivative · entry 2 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,332 Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | ConversionCommon Stock | 166,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | GrantStock Option · Derivative | 31,520 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · derivative · entry 7 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,520 Underlying: Common Stock · 31,520 shares Expires 2026-05-07 F7 · derivative.exercise_date: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date. Read SEC document |
| April 30, 2026 Filed May 4, 2026 22:24 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 3,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-055064 · tm2613528-6_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,286 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary service with the Issuer through the applicable vesting date. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 20:05 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 308 | $52.07 | $16,037.56 |
DisclosureSEC source: 0001104659-26-044359 · tm2612028-1_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,724 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| February 10, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | GrantConvertible Notes · Derivative | 2,000,000 | $2,000,000.00 | $4,000,000,000,000.00 |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · derivative · entry 6 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 166,666 shares Expires not disclosed F1 · derivative.exercise_price: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F6 · date: This transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended, in connection with the Offering, and is reported herein pursuant to Rule 16a-2(a). F1 · derivative.exercise_date: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F1 · derivative.expiration_date: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. Read SEC document |
| February 06, 2026 Filed May 12, 2026 01:58 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | GrantConvertible Notes · Derivative | 3,769,090.08 | $3,769,090.08 | $14,206,040,031,154.41 |
DisclosureSEC source: 0001628280-26-033820 · wk-form4_1778551097.xml · derivative · entry 5 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners Select Fund I, L.P Disclosed balance after: 3,769,090.08 Underlying: Common Stock · 314,090 shares Expires not disclosed F1 · derivative.exercise_price: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F6 · date: This transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended, in connection with the Offering, and is reported herein pursuant to Rule 16a-2(a). F1 · derivative.exercise_date: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. F1 · derivative.expiration_date: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:05 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 181 | $96.47 | $17,461.07 |
DisclosureSEC source: 0001104659-26-005027 · tm263634-1_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,416 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:15 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 221 | $78.84 | $17,423.64 |
DisclosureSEC source: 0001104659-25-100095 · tm2528856-3_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,235 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionConvertible Promissory Note · Derivative | 16,447 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 22 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,447 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F5 · derivative.exercise_date: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F5 · derivative.expiration_date: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionConvertible Promissory Note · Derivative | 1,655 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 21 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By USVP X Affiliates, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,655 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F5 · derivative.exercise_date: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F5 · derivative.expiration_date: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionConvertible Promissory Note · Derivative | 51,736 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 20 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 51,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F5 · derivative.exercise_date: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F5 · derivative.expiration_date: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries F Preferred Stock · Derivative | 37,244 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 19 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By USVP X Affiliates, L.P. Disclosed balance after: 0 Underlying: Common Stock · 37,244 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F4 · shares: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F4 · price: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F4 · derivative.exercise_date: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F4 · derivative.expiration_date: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries F Preferred Stock · Derivative | 1,164,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 18 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,164,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F4 · shares: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F4 · price: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F4 · derivative.exercise_date: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F4 · derivative.expiration_date: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries D Preferred Stock · Derivative | 2,586 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 17 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By USVP X Affiliates, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,586 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · shares: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · derivative.exercise_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · derivative.expiration_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries D Preferred Stock · Derivative | 323 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 16 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By USVP X Affiliates, L.P. Disclosed balance after: 0 Underlying: Common Stock · 323 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · shares: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · derivative.exercise_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · derivative.expiration_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries D Preferred Stock · Derivative | 80,855 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 15 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 80,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · shares: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · derivative.exercise_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · derivative.expiration_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries D Preferred Stock · Derivative | 10,106 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 14 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 10,106 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · shares: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · derivative.exercise_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · derivative.expiration_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries C Preferred Stock · Derivative | 21,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 13 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By USVP X Affiliates, L.P. Disclosed balance after: 0 Underlying: Common Stock · 21,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F2 · shares: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F2 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F2 · derivative.exercise_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F2 · derivative.expiration_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries C Preferred Stock · Derivative | 665,623 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 12 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 665,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F2 · shares: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F2 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F2 · derivative.exercise_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F2 · derivative.expiration_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries B-2 Preferred Stock · Derivative | 7,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 11 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By USVP X Affiliates, L.P. Disclosed balance after: 0 Underlying: Common Stock · 7,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries B-2 Preferred Stock · Derivative | 10,560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 10 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By USVP X Affiliates, L.P. Disclosed balance after: 0 Underlying: Common Stock · 10,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries B-2 Preferred Stock · Derivative | 330,078 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 9 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 330,078 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries B-2 Preferred Stock · Derivative | 220,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 8 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 220,052 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries B-1 Preferred Stock · Derivative | 7,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 7 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By USVP X Affiliates, L.P. Disclosed balance after: 0 Underlying: Common Stock · 7,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries B-1 Preferred Stock · Derivative | 10,560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 6 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By USVP X Affiliates, L.P. Disclosed balance after: 0 Underlying: Common Stock · 10,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries B-1 Preferred Stock · Derivative | 330,078 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 5 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 330,078 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionSeries B-1 Preferred Stock · Derivative | 220,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 4 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 220,052 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionCommon Stock | 16,447 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · nonDerivative · entry 3 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionCommon Stock | 98,303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · nonDerivative · entry 2 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By USVP X Affiliates, L.P. Disclosed balance after: 98,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F2 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F4 · price: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F5 · price: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionCommon Stock | 3,072,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners X, L.P. Disclosed balance after: 3,072,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F2 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F4 · price: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis. F5 · price: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 07, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantStock Option · Derivative | 47,420 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 23 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,420 Underlying: Common Stock · 47,420 shares Expires 2035-08-07 F7 · derivative.exercise_date: The option will vest in full on the earlier of Heartflow's annual meeting of shareholders in 2026 and the first anniversary of the grant date, subject to continued service through such date. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | ConversionSeries E Convertible Preferred Stock · Derivative | 20,504,376 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-022252 · ownership.xml · derivative · entry 8 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,074,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F2 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I-A, L.P. ("USVP Select") and has sole voting and dispositive power with respect to the shares held by USVP Select. F3 · ownership.nature: The Reporting Person, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP Select. Each of the managing members of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. F5 · ownership.nature: Consists of (i) 1,043,988 shares of Common Stock underlying Series C Preferred Stock, 496,309 shares of Common Stock underlying Series D Preferred Stock and 146,106 shares of Common Stock underlying Series E Preferred Stock held by USVP XII; (ii) 52,983 shares of Common Stock underlying Series C Preferred Stock, 25,189 shares of Common Stock underlying Series D Preferred Stock, and 7,415 shares of Common Stock underlying Series E Preferred Stock held by USVP XII-A; and (iii) 921,131 shares of Common Stock underlying Series E Preferred Stock held by U.S. Venture Partners Select Fund I, L.P. on its own behalf and as a nominee for USVP Select. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | ConversionSeries D Convertible Preferred Stock · Derivative | 9,950,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-022252 · ownership.xml · derivative · entry 7 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 521,498 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F2 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I-A, L.P. ("USVP Select") and has sole voting and dispositive power with respect to the shares held by USVP Select. F3 · ownership.nature: The Reporting Person, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP Select. Each of the managing members of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. F5 · ownership.nature: Consists of (i) 1,043,988 shares of Common Stock underlying Series C Preferred Stock, 496,309 shares of Common Stock underlying Series D Preferred Stock and 146,106 shares of Common Stock underlying Series E Preferred Stock held by USVP XII; (ii) 52,983 shares of Common Stock underlying Series C Preferred Stock, 25,189 shares of Common Stock underlying Series D Preferred Stock, and 7,415 shares of Common Stock underlying Series E Preferred Stock held by USVP XII-A; and (iii) 921,131 shares of Common Stock underlying Series E Preferred Stock held by U.S. Venture Partners Select Fund I, L.P. on its own behalf and as a nominee for USVP Select. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | ConversionSeries C Convertible Preferred Stock · Derivative | 20,930,233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-022252 · ownership.xml · derivative · entry 6 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,096,971 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F2 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I-A, L.P. ("USVP Select") and has sole voting and dispositive power with respect to the shares held by USVP Select. F3 · ownership.nature: The Reporting Person, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP Select. Each of the managing members of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. F5 · ownership.nature: Consists of (i) 1,043,988 shares of Common Stock underlying Series C Preferred Stock, 496,309 shares of Common Stock underlying Series D Preferred Stock and 146,106 shares of Common Stock underlying Series E Preferred Stock held by USVP XII; (ii) 52,983 shares of Common Stock underlying Series C Preferred Stock, 25,189 shares of Common Stock underlying Series D Preferred Stock, and 7,415 shares of Common Stock underlying Series E Preferred Stock held by USVP XII-A; and (iii) 921,131 shares of Common Stock underlying Series E Preferred Stock held by U.S. Venture Partners Select Fund I, L.P. on its own behalf and as a nominee for USVP Select. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.